-$0.42 EPS Expected for Kura Oncology Inc (KURA) This Quarter

Analysts expect Kura Oncology Inc (NASDAQ:KURA) to post earnings per share of ($0.42) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.46). Kura Oncology reported earnings of ($0.37) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 13.5%. The firm is scheduled to issue its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($1.72) per share for the current year, with EPS estimates ranging from ($1.76) to ($1.70). For the next year, analysts anticipate that the company will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.73) to ($1.80). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Kura Oncology.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.01.

Several analysts have issued reports on the company. BidaskClub raised Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. Oppenheimer set a $32.00 price target on Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, November 28th. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Kura Oncology in a research note on Monday. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Finally, Piper Jaffray Companies set a $25.00 price target on Kura Oncology and gave the company a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $26.86.

Shares of KURA traded up $0.52 during midday trading on Friday, hitting $13.60. The stock had a trading volume of 241,538 shares, compared to its average volume of 289,108. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $24.02. The company has a market capitalization of $497.52 million, a price-to-earnings ratio of -8.95 and a beta of 4.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76.

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Kura Oncology by 19.7% in the third quarter. BlackRock Inc. now owns 2,396,137 shares of the company’s stock valued at $41,932,000 after acquiring an additional 393,872 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Kura Oncology by 51.4% in the third quarter. Eagle Asset Management Inc. now owns 2,070,417 shares of the company’s stock valued at $36,232,000 after acquiring an additional 703,282 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Kura Oncology by 3.2% in the third quarter. Victory Capital Management Inc. now owns 1,536,310 shares of the company’s stock valued at $26,885,000 after acquiring an additional 47,070 shares during the last quarter. Carillon Tower Advisers Inc. increased its position in shares of Kura Oncology by 62.2% in the third quarter. Carillon Tower Advisers Inc. now owns 1,502,217 shares of the company’s stock valued at $26,288,000 after acquiring an additional 576,221 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Kura Oncology by 2.1% in the third quarter. Vanguard Group Inc. now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after acquiring an additional 29,785 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors and hedge funds.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Why is insider trading harmful?

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply